Completed Phase I dose escalation; results expected in 3Q22 CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Jun. 1, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 26, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the company will present

- Continued clinical progress across pipeline, including interim BT8009 Phase I clinical data - Cash and cash equivalents of $407.4 million as of March 31, 2022 expected to provide financial runway through 2024 CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 5, 2022-- Bicycle Therapeutics plc

- 50% confirmed overall response rate, including one (13%) confirmed complete response in eight urothelial cancer patients dosed at 5.0mg/m 2 weekly - Median duration of response not yet reached in the 2.5mg/m 2 and 5.0mg/m 2 weekly cohorts; four of five responders in these cohorts still on therapy

- Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 8, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 7, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced updated preclinical results

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 6, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management will

- Four Additional Abstracts Selected as Poster Presentations at the Meeting - Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Mar. 8, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Mar. 8, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management will